New Insights on Alzheimer’s Risk and Breast Cancer Survival
There’s a mix of things that raise the risk for Alzheimer’s disease, like genetics, mental health, and even diet. Interestingly, recent research suggests that surviving breast cancer might play a role in this complex picture.
A team of researchers from South Korea discovered that women who have survived breast cancer had an 8 percent lower chance of developing Alzheimer’s, following an average monitoring period of 7.3 years.
According to the study, this reduced risk might be linked to the effects of radiation therapy. This runs counter to some earlier findings that generally associated cancer treatments with a reduction in cognitive abilities, often referred to as “chemobrain.”
“A significant number of breast cancer survivors report issues related to thinking and memory during and after treatment,” the researchers noted.
Despite this, the connection between Alzheimer’s and breast cancer survivors isn’t entirely clear, varying by several factors like age at diagnosis, type of treatment, and time since treatment.
This study analyzed health records from 70,701 patients who had received breast cancer treatment, comparing them to 180,360 healthy individuals. Throughout the study period, the incidence of Alzheimer’s was notably less in the cancer group.
Though the difference might seem small—about 2.45 Alzheimer’s cases expected in 1,000 breast cancer survivors compared to 2.63 in those without cancer—it’s important to remember that the observational nature of the study means we can’t definitively say one causes the other.
But still, this change in risk could accumulate over time, particularly in larger populations, especially when factoring in other influences. The greatest statistical significance in risk reduction was observed among women over 65, likely due to a higher prevalence of Alzheimer’s in older demographics.
Interestingly, those who underwent radiation treatment experienced the most significant risk reduction; however, this effect appeared to diminish over time. This might suggest that we have yet to fully grasp the implications of such treatments, even as radiation has been linked to reducing brain inflammation in prior studies.
“Understanding the risk of Alzheimer’s dementia is immensely important for the well-being of breast cancer survivors,” the researchers emphasized.
While fears about “chemobrain” and the long-lasting cognitive impacts of breast cancer treatments are prevalent, the study suggests that such treatments may not directly lead to Alzheimer’s dementia.
Survival rates for breast cancer continue to improve, and if caught early, over 90 percent of women can expect to survive. Still, it remains the most common cancer among women globally.
This research contributes to a deeper understanding of the potential health issues related to breast cancer and its treatments, particularly in the context of aging—and may even suggest avenues for preventing Alzheimer’s.
“Breast cancer survivors might have a somewhat lower risk of Alzheimer’s compared to those without cancer, a possibility influenced by treatment,” the researchers concluded. They stated that ongoing research is crucial to exploring the long-term neurocognitive outcomes for this demographic.
The findings are published in JAMA Network Open.
